
After sixteen very long years with no truly viable
treatment plans for Alzheimer’s, there’s some optimism on the horizon, in a stunning reversal from the formerly-rejected antibody therapy, aducanumab. The most recent research uncovers that large quantities of this medication do, in fact, lessen cognitive decline at the beginning stages of Alzheimer’s.
[Read More...]